Landscape intelligence
KritRNA maps the premature-stop landscape at variant, gene, transcript and disease-mechanism level so programme selection begins with biological relevance rather than raw mutation counts.
Explore the problem landscape →Evidence at KritRNA
Evidence that moves
programmes forward.
KritRNA is building a public-facing evidence layer that shows why suppressor tRNA matters, how programmes are selected and which scientific questions create the next value inflection point—without disclosing candidate sequences, confidential rankings or unfiled intellectual property.
Decision architecture
From a large biological opportunity to focused therapeutic programmes.
The strength of a platform is not the volume of data it collects. It is the quality of the decisions that data enables.
Candidate-quality gates
Charging, transcript context, binding-tissue delivery and native-stop safety form the four decisive gates through which every therapeutic concept must pass.
See the scientific gates →Programme selection
Disease opportunity is assessed across mechanism, addressable mutation burden, restoration logic, delivery feasibility, model availability, India relevance and development fit.
Review the programme logic →India-originated capability
KritRNA is building population-aware evidence and therapeutic origination capability from India while aligning development decisions with global scientific standards.
Understand the India strategy →Public evidence standard
Clear about what is known. Precise about what comes next.
KritRNA separates direct evidence, scientific inference and future validation so collaborators and investors can see how each decision is supported and how uncertainty becomes an executable development plan.
Measured
Directly supported by a cited dataset, publication or experimental result.
Inferred
A reasoned conclusion derived from available evidence and labelled accordingly.
To be tested
A defined question that becomes a specific experiment, collaboration or milestone.
Build with us
The next layer of evidence is created through collaboration.
KritRNA is seeking scientific, CRO, delivery, disease-model and strategic partners who can help convert rigorous programme logic into proprietary experimental evidence.